$LLY News

Eli Lilly (LLY) To Share New Kisunla And Alzheimer’s Blood Test Data At AAIC

B of A Securities Maintains Buy on Eli Lilly, Raises Price Target to $1334

Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN

Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma

/C O R R E C T I O N -- Eli Lilly and Company/

Eli Lilly Stock Gets a Lift After Canada Backs Eczema Drug

3 High Growth GLP-1 Biotech Winners to Buy in July

Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment

Eli Lilly Highlights Alzheimer’s Research With 16 Abstracts At AAIC 2026, Including Three Oral Presentations

JPMorgan resets LLY stock target on drug demand

Innovent’s China Verzenios Deal and New Jaypirca Nod Might Change The Case For Investing In Eli Lilly (LLY)

Is It Too Late to Buy Eli Lilly?

Eli Lilly Estimates $2.8B Q2 2026 Acquired IPR&D Charges, Impacting GAAP And Non-GAAP EPS By ~$3.02 Per Share

Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity

Eli Lilly Expected to Beat Q2 Revenue Forecasts on Weight-Loss Drugs, RBC Says

Eli Lilly Weight-Loss, Diabetes Franchise to Drive Second Quarter Sales Beat, RBC Says

LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now?

Truist Securities Maintains Buy on Eli Lilly, Raises Price Target to $1370

Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026

Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1347